2026年全球技术报告：生命科学行业洞察

KPMG. Make the Difference.KPMG International | kpmg.comKPMG Global tech report 2026: Life SciencesValue realization AuthorsRecommendationsMethodologyKey findingsTechnology investment Technology adoption and maturity ForewordForewordThis report provides a snapshot on technology adoption, investment, and value realization within the Life Sciences sector. The research is based on a global survey of 124 Life Sciences tech function leaders in large and mid-sized pharmaceutical, biotechnology and medical device companies; as well as product distributors, and contract research organizations.The findings suggest the sector has progressed beyond experimentation into broad adoption of core technologies. Investment remains measured, with organizations prioritizing stability and compliance over rapid expansion. Overall, the sector remains in the early phases of maturity and value realization, with most benefits concentrated primarily towards operational efficiency rather than transformational growth.The results also highlight a gap between technology ambitions and the actions required to deliver them. Our data shows that, although the industry has demonstrated the effectiveness of digital technology and is enabling returns on investment, challenges remain in securing funding, establishing governance, and achieving large-scale implementation.To optimize operations and support a more collaborative, innovative, and patient-focused future, Life Sciences companies should make more decisive technology moves that rebalance risk — away from adoption and compliance, towards scale, speed, and value capture.We hope the perspectives shared in this report support informed decision-making in a rapidly evolving landscape.Liz Claydon Global Head of Life Sciences and Global Head of Deal Advisory KPMG InternationalKPMG Global tech report 2026: Life Sciences | 2© 2026 Copyright owned by one or more of the KPMG International entities. KPMG International entities provide no services to clients. All rights reserved.Value realization AuthorsRecommendationsMethodologyForewordTechnology investment Technology adoption and maturity Key findingsKey findings trust AI outputs for strategic and operational decisions75%Technology adoption and maturityWhat Life Sciences technology function leaders are saying about…have integrated AI agents into workflows, products, and servicesLow maturity reported in enterprise data management, cloud infrastructure and technology sourcing and vendor managementInvestmentsValue realization Most are balancing maintenance of existing systems with capability upgradesA mix of build-and-buy is their preferred model for capacity buildingLife Sciences significantly trails other industries in scaling XaaS, Web3, VR/AR/XR, digital twins and AI/automationNearly half (48%) are achieving significant value realization on their technology investments, yet 93% report digital initiatives generate less than 1% of annual revenue —87%allocate less than 1% of annual r